Seres Therapeutics Inc. (MCRB) Trading Up 3.4%
Seres Therapeutics Inc. (NASDAQ:MCRB) was up 3.4% during mid-day trading on Tuesday . The company traded as high as $11.30 and last traded at $11.06, with a volume of 546,986 shares traded. The stock had previously closed at $10.70.
A number of equities research analysts recently issued reports on MCRB shares. HC Wainwright started coverage on shares of Seres Therapeutics in a report on Friday, July 29th. They issued a “buy” rating and a $50.00 price objective for the company. FBR & Co decreased their price target on shares of Seres Therapeutics from $43.00 to $23.00 and set an “outperform” rating for the company in a report on Friday. Zacks Investment Research cut shares of Seres Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, July 19th. Cowen and Company restated a “buy” rating on shares of Seres Therapeutics in a report on Friday, July 29th. Finally, Bank of America Corp. cut shares of Seres Therapeutics from a “buy” rating to a “neutral” rating in a report on Monday, August 1st. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $31.57.
The company’s market capitalization is $448.81 million. The company’s 50-day moving average price is $24.28 and its 200 day moving average price is $26.75.
Seres Therapeutics (NASDAQ:MCRB) last issued its quarterly earnings data on Thursday, August 11th. The company reported ($0.70) EPS for the quarter, missing analysts’ consensus estimates of ($0.46) by $0.24. The company had revenue of $3 million for the quarter, compared to analyst estimates of $4.20 million. The firm’s revenue for the quarter was up NaN% compared to the same quarter last year. During the same quarter last year, the firm posted ($1.45) EPS. On average, equities research analysts forecast that Seres Therapeutics Inc. will post ($2.14) EPS for the current fiscal year.
In related news, insider Michele Trucksis sold 4,156 shares of the firm’s stock in a transaction on Thursday, July 28th. The shares were sold at an average price of $35.18, for a total transaction of $146,208.08. Following the sale, the insider now directly owns 4,156 shares in the company, valued at $146,208.08. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider John G. Aunins sold 9,390 shares of the firm’s stock in a transaction on Monday, July 25th. The stock was sold at an average price of $34.18, for a total transaction of $320,950.20. Following the sale, the insider now owns 220,155 shares in the company, valued at $7,524,897.90. The disclosure for this sale can be found here.
A hedge fund recently raised its stake in Seres Therapeutics stock. Morgan Stanley raised its stake in shares of Seres Therapeutics Inc. (NASDAQ:MCRB) by 225.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 33,758 shares of the company’s stock after buying an additional 23,381 shares during the period. Morgan Stanley owned about 0.09% of Seres Therapeutics worth $1,185,000 at the end of the most recent quarter.
Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.